Lopinavir And Ritonavir Tablets

Lopimune(Generic Lopinavir and Ritonavir Tablets) - Product Information

Lopimune(Generic Lopinavir and Ritonavir Tablets) is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older)
Genotypic or phenotypic testing and/or treatment history should guide the use of Lopimune Tablets. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to Lopimune Tablets.
We also have in stock Atavir (Atazanavir Sulfate Capsules) which is is used together with other medicines for the treatment of the infection caused by the human immunodeficiency virus (HIV) in adults and in pediatric patients.

Name of the Drug

Lopimune Tablets.

Manufacturer of Lopimune Tablets

Cipla Limited, India  
Website: www.cipla.com

Active Pharmaceutical Ingredient

The active ingredients present in Lopimune tablets are Lopinavir and Ritonavir. Each film-coated Lopimune tablet contains 200 mg of Lopinavir and 50 mg Ritonavir

Uses of Lopimune(Generic Lopinavir and Ritonavir Tablets)

Lopinavir and ritonavir combination is used with other medicines in the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus responsible for acquired immune deficiency syndrome (AIDS). It is used to slow the progression of disease in patients infected with HIV who have advanced symptoms, early symptoms, or no symptoms at all.
Lopinavir and ritonavir combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay the development of problems usually related to AIDS or HIV disease. Lopinavir and ritonavir combination will not keep you from spreading HIV to other people. People who receive this medicine may continue to have other problems usually related to AIDS or HIV disease.

Lopimune(Generic Lopinavir and Ritonavir Tablets) - Dosage

Generic Lopinavir and Ritonavir tablets should be administered exactly as suggested by your doctor. Your doctor may recommend a dosage of Lopimune tablets depending on your age, medical requirement, body weight, other medical conditions, and current medications.
Lopimune Tablets may be taken with or without food. The tablets should be swallowed whole and not chewed, broken, or crushed. Dosage Recommendations in Adults
Lopimune can be given in once daily or twice daily dosing regimen at dosages noted below.
Lopimune Tablets once daily dosing regimen is not recommended in:

• Adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.
• In combination with carbamazepine, phenobarbital, or phenytoin.
• In combination with efavirenz, nevirapine, or nelfinavir.
• In pregnant women.

Recommended Once daily Dosage
200 mg/50 mg Tablets 800 mg/200 mg (4 tablets)
Recommended Twice daily Dosage
200 mg/50 mg Tablets 400 mg/100 mg (2 tablets)
The dose of Lopimune Tablets must be increased when administered in combination with efavirenz, nevirapine or nelfinavir.
Dosage Recommendations in Pregnancy
Administer 400/100 mg of Lopimune Tablets twice daily in pregnant patients with no documented lopinavir-associated resistance substitutions.
Once daily Lopimune Tablets dosing is not recommended in pregnancy
There are insufficient data to recommend dosing in pregnant women with any documented lopinavir-associated resistance substitutions.
No dosage adjustment of Lopimune Tablets is required for patients during the postpartum period.
Lopimune tablets work effectively if the amount of Lopinavir and Ritonavir is maintained at a constant level in the body. You should be systematic about the daily schedule for the medication such that you take Lopimune tablets at about the same time every day, to get the maximum benefit of the medication. Continue taking tablets without missing any doses for the recommended treatment period and do not stop the treatment suddenly even if you feel better.

Please consult your doctor for exact dosing instructions. Lopimune tablets (Generic Lopinavir and Ritonavir tablets) should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Missed Dose

If you forget to take your regular tablet dose on time, take it whenever you remember.
If you remember the next day, skip the missed dose and take your scheduled dose. Do not take a double dose to compensate the missed dose.

Mechanism of Action

Lopinavir and ritonavir are antiretroviral medications primarily used in combination therapy to treat human immunodeficiency virus (HIV) infection. Their mechanism of action involves targeting a critical step in the HIV life cycle: viral protease activity.
Lopinavir acts as a highly potent and selective HIV-1 protease inhibitor. The HIV protease is an essential enzyme involved in the processing of viral proteins (gag and gag-pol polyproteins). This cleavage is necessary for the virus to produce mature, infectious particles that can go on to infect other cells. By inhibiting HIV protease, lopinavir prevents this cleavage, leading to the formation of immature, non-infectious viral particles and effectively halting viral replication.
Ritonavir also belongs to the class of HIV protease inhibitors. However, in the lopinavir/ritonavir combination (marketed as Kaletra), ritonavir is primarily used in a low dose as a pharmacokinetic enhancer. Ritonavir is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme in the liver, notes DrugBank. CYP3A4 is the primary enzyme responsible for metabolizing and eliminating lopinavir from the body. By inhibiting CYP3A4, ritonavir reduces the metabolism of lopinavir, thereby increasing and prolonging the concentration of lopinavir in the bloodstream. This "boosting" effect allows for more sustained and effective antiviral activity from lopinavir with lower doses.

Storage Instructions for Lopimune(Generic Lopinavir and Ritonavir Tablets)

Store Lopimune at controlled room temperature (20°C to 25°C),protected from heat, moisture, and sunlight. Excursions are permitted from 15°C to 30°C.
Retain the original packing of the medication and do not consume past its expiration date printed on the blister pack. Keep the pack of Lopimune tablets away from the reach of children and pets. Do not dispose Generic Lopinavir and Ritonavir Tablets along with domestic waste or sewage. Consult your doctor or pharmacist about the correct method of disposal.

Contraindications

Lopimune tablets are contraindicated in patients with a hypersensitivity to Lopinavir and Ritonavir (e.g., toxic epidermal necrolysis, Stevens- Johnson syndrome, erythema multiforme, urticaria, angioedema) or any inactive ingredient present in tablets. Lopimune tablets are contraindicated in the following cases:

• Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated plasma levels may result in serious and/or life- threatening events.
• Co-administration with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross resistance

Overdose

Overdoses with Lopinavir and Ritonavir oral solution have been reported. One of these reports described fatal cardiogenic shock in a 2.1 kg infant who received a single dose of 6.5 mL of Lopinavir and Ritonavir oral solution (520 mg lopinavir, approximately 10-fold above the recommended lopinavir dose) nine days prior. The following events have been reported in association with unintended overdoses in preterm neonates: complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure. Human experience of acute overdosage with Lopinavir and Ritonavir is limited. Treatment of overdose with Lopinavir and Ritonavir should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with Lopinavir and Ritonavir tablets. If indicated, elimination of unabsorbed drug should be achieved by gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug.

Warnings and Precautions

The following have been observed in patients receiving Lopimune :

• The concomitant use of Lopimune and certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions.
• Toxicity in preterm neonates: Lopinavir and Ritonavir oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of Lopinavir and Ritonavir in this patient population has not been established.
• Pancreatitis: Fatalities have occurred; suspend therapy as clinically appropriate.
• Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations.
• QT interval prolongation and isolated cases of torsade de pointes have been reported although causality could not be established. Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval.
• PR interval prolongation may occur in some patients. Cases of second and third degree heart block have been reported. Use with caution in patients with pre-existing conduction system disease, ischemic heart disease, cardiomyopathy, underlying structural heart disease or when administering with other drugs that may prolong the PR interval.
• Patients may develop new onset or exacerbations of diabetes mellitus, hyperglycemia , immune reconstitution syndrome, redistribution/accumulation of body fat.
• Total cholesterol and triglycerides elevations. Monitor prior to therapy and periodically thereafter.
• Hemophilia: Spontaneous bleeding may occur, and additional factor VIII may be required

Side Effects of Lopimune Tablets

Commonly reported Lopimune side effects included diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. These are not all of the possible side effects of Lopimune Tablets. For more information, ask your healthcare provider or pharmacist.

Lopinavir and Ritonavir Tablets During Pregnancy

Lopinavir and Ritonavir Tablets has been classified by the US FDA as Pregnancy Category C.
Available data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major birth defects compared to the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). No treatment-related malformations were observed when lopinavir in combination with ritonavir was administered to pregnant rats or rabbits; however embryonic and fetal developmental toxicities occurred in rats administered maternally toxic doses.

Nursing Considerations

HIV-1-infected mothers should not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. Because of the potential for HIV-1 transmission mothers should be instructed not to breastfeed.
Do not breast-feed a baby if you are using Lopimune(Generic Lopinavir and Ritonavir Tablets) .

Buy Lopinavir and Ritonavir Pills Online From Only $1.78 per Pill

You can buy Lopinavir and Ritonavir Tablets online from Everest Online Pharmacy at a cheap price. Lopimune 250 mg ( 200 mg of Lopinavir and 50 mg of Ritonavir) pills, manufactured by Cipla Ltd., India are supplied in a blister strip of 10 tablets. The 250 mg tablets cost only $1.78 per unit when you place an order for 360 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith. It is without a warrant of any kind, expressed or implied.

Shipping Restriction